WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors

Frizzled-7 as a Potential Therapeutic Target in Colorectal Cancer

(2015) Koji Ueno et al.   NEOPLASIA

Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant Melanoma

(2015) William D. Tap et al.   NEOPLASIA

WNT5A-NFAT Signaling Mediates Resistance to Apoptosis in Pancreatic Cancer

(2015) Heidi Griesmann et al.   NEOPLASIA

Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2

(2013) M. P. O'Connell et al.   Cancer Discovery

The Role of the PI3K-AKT Pathway in Melanoma

(2012) Michael A. Davies   CANCER JOURNAL

Interference of Frizzled 1 (FZD1) reverses multidrug resistance in breast cancer cells through the Wnt/β-catenin pathway

(2012) Hui Zhang et al.   CANCER LETTERS

BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma

(2012) Y Shao et al.   CELL DEATH AND DIFFERENTIATION

WLS inhibits melanoma cell proliferation through the β-catenin signalling pathway and induces spontaneous metastasis

(2012) Pei-Tzu Yang et al.   EMBO Molecular Medicine

Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma

(2012) Vipin Yadav et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With MetastaticBRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor

(2012) Kevin B. Kim et al.   JOURNAL OF CLINICAL ONCOLOGY

Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition

(2012) Kavitha Gowrishankar et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

MDM4 is a key therapeutic target in cutaneous melanoma

(2012) Agnieszka Gembarska et al.   NATURE MEDICINE

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

ROR1 Is Expressed in Human Breast Cancer and Associated with Enhanced Tumor-Cell Growth

(2012) Suping Zhang et al.   PLoS One

Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors

(2012) A. Gurney et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Wnt5a: its signalling, functions and implication in diseases

(2011) A. Kikuchi et al.   Acta Physiologica

Dual inhibition of V600EBRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism

(2011) Irene Sánchez-Hernández et al.   CANCER LETTERS

Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation

(2011) F. Su et al.   CANCER RESEARCH

Ror1 Is a Pseudokinase That Is Crucial for Met-Driven Tumorigenesis

(2011) A. Gentile et al.   CANCER RESEARCH

PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression

(2011) K. H. T. Paraiso et al.   CANCER RESEARCH

Frizzled7 as an emerging target for cancer therapy

(2011) Taj D. King et al.   CELLULAR SIGNALLING

Mindbomb 1, an E3 ubiquitin ligase, forms a complex with RYK to activate Wnt/β-catenin signaling

(2011) Jason D. Berndt et al.   JOURNAL OF CELL BIOLOGY

Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

(2011) Nikhil Wagle et al.   JOURNAL OF CLINICAL ONCOLOGY

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

(2011) Poulikos I. Poulikakos et al.   NATURE

Wnt7a–Fzd7 signalling directly activates the Akt/mTOR anabolic growth pathway in skeletal muscle

(2011) Julia von Maltzahn et al.   NATURE CELL BIOLOGY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

A protein complex of SCRIB, NOS1AP and VANGL1 regulates cell polarity and migration and is associated with breast cancer progression

(2011) J N Anastas et al.   ONCOGENE

FZD7 has a critical role in cell proliferation in triple negative breast cancer

(2011) L Yang et al.   ONCOGENE

Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition

(2011) W. Deng et al.   Pigment Cell & Melanoma Research

A Switch from Canonical to Noncanonical Wnt Signaling Mediates Drug Resistance in Colon Cancer Cells

(2011) Michael Bordonaro et al.   PLoS One

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway

(2011) Mohammad Atefi et al.   PLoS One

WNT5A antagonizes WNT/β-catenin signaling and is frequently silenced by promoter CpG methylation in esophageal squamous cell carcinoma

(2010) Jisheng Li et al.   CANCER BIOLOGY & THERAPY

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf-Mutant Human Cutaneous Melanoma Cells

(2010) Y. N. V. Gopal et al.   CANCER RESEARCH

Akt3-Mediated Resistance to Apoptosis in B-RAF-Targeted Melanoma Cells

(2010) Y. Shao et al.   CANCER RESEARCH

Gene signature of the metastatic potential of cutaneous melanoma: too much for too little?

(2010) József Tímár et al.   CLINICAL & EXPERIMENTAL METASTASIS

MEK-Independent Survival of B-RAFV600E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX4720

(2010) C. C. Jiang et al.   CLINICAL CANCER RESEARCH

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

(2010) Gideon Bollag et al.   NATURE

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

(2010) E. W. Joseph et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Down-regulation of frizzled-7 expression decreases survival, invasion and metastatic capabilities of colon cancer cells

(2009) K Ueno et al.   BRITISH JOURNAL OF CANCER

Small-Molecule Inhibitors of Phosphatidylinositol 3-Kinase/Akt Signaling Inhibit Wnt/ -Catenin Pathway Cross-Talk and Suppress Medulloblastoma Growth

(2009) N. Baryawno et al.   CANCER RESEARCH

Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling

(2009) Shih-Min A. Huang et al.   NATURE

An olive branch to two theories

(2009) Leonie Welberg   NATURE REVIEWS NEUROSCIENCE

The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma

(2009) M P O’Connell et al.   ONCOGENE

Activated Wnt/ss-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model

(2009) A. J. Chien et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Modeling Genomic Diversity and Tumor Dependency in Malignant Melanoma

(2008) W. M. Lin et al.   CANCER RESEARCH

WNT5A Exhibits Tumor-Suppressive Activity through Antagonizing the Wnt/ -Catenin Signaling, and Is Frequently Methylated in Colorectal Cancer

(2008) J. Ying et al.   CLINICAL CANCER RESEARCH

WNT5A Expression Increases during Melanoma Progression and Correlates with Outcome

(2008) P. D. Da Forno et al.   CLINICAL CANCER RESEARCH

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

(2008) J. Tsai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Wnt5a Control of Cell Polarity and Directional Movement by Polarized Redistribution of Adhesion Receptors

(2008) E. S. Witze et al.   SCIENCE